Literature DB >> 12543784

A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis.

Elizabeth A Herness1, Rajesh K Naz.   

Abstract

Prostate-specific genes that have a role in normal and abnormal prostate growth are needed for early and specific diagnosis and treatment of prostate cancer. In the present study, the differential display-PCR technique was used to obtain a prostate-specific approximately 339-bp cDNA fragment. On screening the human-prostate lambdagt10 library with this fragment, a full-length 1468-bp human prostate-specific gene (HPG-1) with an open reading frame of 127 amino acids (aa) was retrieved. Extensive database search revealed that the HPG-1 has novel nucleotide/aa sequences. It was localized on Homo sapiens 3q26 chromosomal locus, a region that has been shown to be involved in prostate carcinoma. The computer-generated translated protein has a calculated molecular mass of 14.8 kDa with several potential glycosylation and phosphorylation sites including two N-linked glycosylation, one tyrosine phosphorylation, and one N-myristoylation sites. The in vitro transcription and translation procedures using HPG-1 cDNA yielded a protein of similar molecular mass of approximately 15 kDa. Hydrophilicity analysis of the deduced aa sequence indicated that HPG-1 is a membrane-anchored/attached protein. Analysis for tissue specificity by using the Northern blot and reverse transcription-PCR-Southern blot procedures using 19 different human tissues revealed that HPG-1 is expressed specifically only in prostate tissue. To examine its involvement in prostate carcinogenesis, three prostate cancer epithelial cell lines, one androgen-responsive (LNCaP) and two androgen-nonresponsive (DU-145 and PC-3), were examined for the expression of HPG-1. Using the Northern blot and quantitative reverse transcription-PCR procedures it was found that LNCaP and DU-145 cells and not the PC-3 cells have HPG-1 expression, with LNCaP cells having approximately 2-3-fold higher levels of HPG-1 mRNA transcripts compared with DU-145 cells. In vitro culture of LNCaP cell with antisense and not the sense oligonucleotide decreased the HPG-1 mRNA levels and inhibited the cell growth in a concentration-dependent manner; at 72 h there was an 86% inhibition of cell growth. HPG-1 mRNA expression in LNCaP cells was found to be responsive to androgen. Thus, the novel androgen-responsive HPG-1, which has prostate-specific expression and seems to be involved in carcinogenesis, may have applications in the specific diagnosis and treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543784

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

Review 2.  The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.

Authors:  Yong Luo; Xin Gou; Peng Huang; Chan Mou
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

Review 3.  Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.

Authors:  Yong Cui; Wenzhou Cao; Quan Li; Hua Shen; Chao Liu; Junpeng Deng; Jiangfeng Xu; Qiang Shao
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

4.  Effect of upregulation of DD3 on early detection and prognosis in prostate cancer.

Authors:  Ke Wang; Huishan Zhao; Wenting Wang; Yingqian Zhu; Xuebao Zhang; Jiajia Ma; Haotian Tan; Yulian Zhang; Chunhua Lin
Journal:  Transl Androl Urol       Date:  2020-08

5.  Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.

Authors:  A Kiessling; S Stevanovic; S Füssel; B Weigle; M A Rieger; A Temme; E P Rieber; M Schmitz
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.